Thomas Gad Sells 7,250 Shares of Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Stock

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) CEO Thomas Gad sold 7,250 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $16.71, for a total transaction of $121,147.50.

Thomas Gad also recently made the following trade(s):

  • On Monday, October 21st, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $31.65, for a total transaction of $126,600.00.
  • On Monday, October 7th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $25.21, for a total transaction of $100,840.00.
  • On Monday, September 16th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $30.59, for a total transaction of $122,360.00.
  • On Tuesday, September 3rd, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $25.77, for a total transaction of $103,080.00.
  • On Monday, August 19th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $27.70, for a total transaction of $110,800.00.
  • On Monday, August 5th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $21.78, for a total transaction of $87,120.00.

Shares of YMAB stock opened at $31.95 on Tuesday. Y-mAbs Therapeutics, Inc has a 12 month low of $15.17 and a 12 month high of $32.90. The company has a quick ratio of 9.04, a current ratio of 9.04 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average is $27.88 and its two-hundred day moving average is $24.47. The company has a market cap of $1.03 billion and a PE ratio of -21.30.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.05). As a group, equities analysts expect that Y-mAbs Therapeutics, Inc will post -2.1 EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the business. Bank of Montreal Can acquired a new position in Y-mAbs Therapeutics during the second quarter valued at approximately $39,000. Swiss National Bank acquired a new position in Y-mAbs Therapeutics during the second quarter valued at approximately $290,000. Tuttle Tactical Management acquired a new position in Y-mAbs Therapeutics during the third quarter valued at approximately $309,000. Wells Fargo & Company MN grew its holdings in Y-mAbs Therapeutics by 422.2% during the second quarter. Wells Fargo & Company MN now owns 19,203 shares of the company’s stock valued at $438,000 after purchasing an additional 15,526 shares during the last quarter. Finally, Strs Ohio grew its holdings in Y-mAbs Therapeutics by 1,063.2% during the third quarter. Strs Ohio now owns 22,100 shares of the company’s stock valued at $575,000 after purchasing an additional 20,200 shares during the last quarter. Institutional investors own 31.69% of the company’s stock.

YMAB has been the topic of several recent research reports. HC Wainwright set a $40.00 price objective on shares of Y-mAbs Therapeutics and gave the company a “buy” rating in a research report on Monday, August 26th. Wedbush initiated coverage on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 3rd. They set an “outperform” rating and a $38.00 price objective on the stock. ValuEngine lowered shares of Y-mAbs Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, October 17th. Zacks Investment Research reaffirmed a “hold” rating on shares of Y-mAbs Therapeutics in a research report on Saturday, October 12th. Finally, Cowen reaffirmed a “buy” rating on shares of Y-mAbs Therapeutics in a research report on Monday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $34.67.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

See Also: Why is cost of goods sold important?

Insider Buying and Selling by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.